VKTX - Viking Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $93.60 DETAILS

Stock News

Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $39.97, moving 5.13% from the previous trading session.

Jul 08, 2026 02:51 PM • zacks.com

Chip Rout Drags Nasdaq 100 Lower, Oil Climbs: Stock Market Today

A deepening sell-off in chip and memory stocks dragged all four major U.S. equity indexes lower by midday Tuesday.

Jul 07, 2026 09:20 AM • benzinga.com

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?

CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pipeline.

Jul 07, 2026 06:36 AM • fool.com

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding obesity and metabolic disorder markets.

Jul 06, 2026 03:35 AM • fool.com

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Jul 06, 2026 03:15 AM • fool.com

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?

Viking Therapeutics could have a medicine on the market within two years. To capture market share, the new offering will need to fight a pair of pharma juggernauts.

Jul 04, 2026 09:05 PM • fool.com

Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying

Viking Therapeutics is studying its weight loss drug candidate in late-stage trials. If all goes smoothly, the biotech could enter a market nearing $100 billion in the next few years.

Jul 04, 2026 01:10 AM • fool.com

Here's Why Viking Therapeutics Stock Surged Higher in June

Viking's VK2735 has advantages over other weight-loss drugs, and investors anticipate positive results from Phase 3 trials in the coming years. The development of VK2735 as a dual formulation therapy could be the key to unlocking value for investors.

Jul 03, 2026 05:25 AM • fool.com

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $37.48, denoting a -3.92% move from the preceding trading day.

Jul 01, 2026 02:51 PM • zacks.com

Is Viking Therapeutics Stock Going to $100?

Viking Therapeutics' pipeline includes several promising weight-loss candidates. The stock could soar in the next 18 months, but there is plenty of risk involved.

Jul 01, 2026 10:00 AM • fool.com

Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate

Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current ~$5B valuation amid sector momentum. Novo Nordisk's oral Wegovy launch sets a new benchmark, highlighting peptide-based oral GLP-1 drugs' commercial potential and raising the value of VKTX's oral program. VKTX's injectable VK2735 faces intensified competition after Eli Lilly's Retatrutide Phase III results, which establish a higher efficacy standard (>24%).

Jun 30, 2026 10:32 AM • seekingalpha.com

Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?

NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.

Jun 29, 2026 08:11 AM • zacks.com

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Jun 29, 2026 06:31 AM • zacks.com

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could

Unlike SpaceX, ADMA Biologics is already profitable and has a clear path to doubling over the near term. EyePoint Pharmaceuticals could soon be a key player in a $15 billion global market.

Jun 29, 2026 12:44 AM • fool.com

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.

Jun 26, 2026 07:05 AM • fool.com

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $36.97, denoting a -2.38% move from the preceding trading day.

Jun 25, 2026 02:45 PM • zacks.com

VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug

Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.

Jun 25, 2026 07:01 AM • zacks.com

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the initiation of a Phase 1 single ascending dose (SAD) clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). VK3019 is being developed as a potential treatment option for weight loss.

Jun 24, 2026 03:05 AM • prnewswire.com

Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?

Eli Lilly is already a market leader in the GLP-1 market, but its high valuation could limit future gains. Viking Therapeutics doesn't have an approved product just yet, but VK2735 has shown a lot of promise in clinical trials.

Jun 23, 2026 06:14 AM • fool.com

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?

Jun 23, 2026 03:55 AM • 247wallst.com